On September 19, 2020, Lotus Pharmaceutical Co., Ltd. (“Lotus”) and Chong Kun Dang Pharmaceutical Corp. (“CKD”) announced that they have entered into a commercialization agreement in connection with CKD’s biosimilar darbepoetin alfa, a second-generation epoetin indicated for the treatment of anemia associated with chronic renal failure.  According to Lotus’ press release, the long-term strategic partnership gives Lotus exclusive rights to market darbepoetin alfa in Taiwan and South East Asian markets. This is the fifth biosimilar in Lotus’ pipeline of products, including bevacizumab, adalimumab, trastuzumab and teriparatide, targeted for Asian markets.